secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolus, Inc. (EOLS)
CIK:        0001570562
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001570562-22-000064
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolus Q4 revenue $34.7M (+68% YoY); 2021 revenue $99.7M (+76%); 2022 guidance $143-150M reaffirmed
--------------------------------------------------------------------------------

- Q4 2021 net revenue $34.7M, up 68% from Q4 2020; full-year revenue $99.7M, up 76% over 2020.
- Cash and cash equivalents $146.3M at Dec 31, 2021, including $68.7M from first tranche of $125M term loan.
- Reaffirmed FY2022 revenue guidance of $143-150M (43-50% YoY growth); expects adjusted gross margin 58-61%.
- Added 400 new accounts in Q4 and 1,400 in 2021; total accounts >7,000 with reorder rate >70%.
- Phase II extra-strength Jeuveau study on track for first patient Q1 2022; Nuceiva EU launch planned Q3 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1570562/000157056222000064/0001570562-22-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1570562/000157056222000064/eols-20220303.htm
  HTML page:      https://secwatch.observer/filing/0001570562-22-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer